Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy

NCT00880360 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT00880360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00880360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
April 30, 2010
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, extraovarian peritoneal cancer, fallopian tube carcinoma